Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Safety and Effectiveness of Cinnomer® on Disease Characteristics, Depression, and Quality of Life of Patients With Multiple Sclerosis: A Phase Iv, Post-Marketing, Prospective, Multicenter Study Publisher Pubmed



Moghadasi AN1 ; Ashtari F2 ; Baghbanian SM3 ; Shaygannejad V2 ; Anjidani N4 ; Ghadiri F1 ; Sedighi B5 ; Saeidi M6 ; Amirifard H7 ; Ayromlou H8 ; Moghadam NB9 ; Ranjbar MB10 ; Nazeri M11 ; Niknam Z12 Show All Authors
Authors
  1. Moghadasi AN1
  2. Ashtari F2
  3. Baghbanian SM3
  4. Shaygannejad V2
  5. Anjidani N4
  6. Ghadiri F1
  7. Sedighi B5
  8. Saeidi M6
  9. Amirifard H7
  10. Ayromlou H8
  11. Moghadam NB9
  12. Ranjbar MB10
  13. Nazeri M11
  14. Niknam Z12
  15. Faraji F13
  16. Afsorde A14
  17. Sahraian MA1
Show Affiliations
Authors Affiliations
  1. 1. Multiple Sclerosis Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Isfahan University of Medical Sciences, Kashani Comprehensive MS Center, Isfahan, Iran
  3. 3. Multiple Sclerosis Fellowship, Neurology Department, Boualicina Hospital, Mazandaran University of Medical Sciences, Sari, Iran
  4. 4. Medical Department, Orchid Pharmed Company, Tehran, Iran
  5. 5. Neurology Research Center, Kerman University of Medical Science, Kerman, Iran
  6. 6. Department of Neurology, Ghaem Hospital, Mashhad University of Medical Sciences, Mashhad, Iran
  7. 7. Department of Neurology, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran
  8. 8. Neurology Department, Imam Reza Hospital, Tabriz University of Medical Sciences, Tabriz, Iran
  9. 9. Department of Neurology, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  10. 10. Pastour Building, Shiraz, Iran
  11. 11. Clinical Neurology Research Center, Department of Neurology, Shiraz University of Medical Sciences, Shiraz, Iran
  12. 12. Kosar Hospital, Shiraz, Iran
  13. 13. Department of Neurology, School of Medicine, Arak University of Medical Sciences, Arak, Iran
  14. 14. Sina Building, Shiraz, Iran

Source: Archives of Iranian Medicine Published:2023


Abstract

Background: Every patient diagnosed with definite multiple sclerosis (MS) should begin disease modifying therapies. Cinnomer® contains 40 mg glatiramer acetate (GA) and is available in prefilled syringes and autoinjector devices. Methods: A phase IV multicenter study was conducted to explore the safety and effectiveness of Cinnomer® in the treatment of MS. Study-related data were collected for 14 months. Results: Totally, 368 Iranian relapsing-remitting MS patients in nine cities were enrolled. The patients were either treatment naive (n = 191) or switchers (n = 177). Cinnomer® treatment was associated with a significant reduction in annual relapse rate (ARR) (RR: 0.65, 95% CI: 0.43, 0.98). Final mean Expanded Disability Status Scale (EDSS) scores showed improvement from baseline (difference: -0.21, 95% confidence interval (CI): -0.34, -0.08). There was a significant decrease in gad-enhancing lesions during treatment (difference: -0.38, 95% CI: -0.64, -0.12). The mean score for the depression measure (21-item BDI-II questionnaire) significantly improved (difference: -2.39, 95% CI: -3.74, -1.03). There was a significant change in the psychological well-being dimension (P = 0.02) (in line with BDI-II scores) and rejection MusiQoL dimensions (P = 0.04). The adverse events documented throughout the study were not unexpected for GA and were principally not serious. Conclusion: Safety measures were in line with the known profiles of GA. The results suggest that Cinnomer® is effective with respect to clinical outcomes and from the patient's perspective and in reducing MRI-measured MS activity. © 2023 Academy of Medical Sciences of I.R. Iran. All rights reserved.
Related Docs
View other Related Docs
1. A Report of Multiple Sclerosis Patients Treated by Cinnovex™ in Iran, Tehran University Medical Journal (2010)
2. Prescription Trends of Disease-Modifying Treatments for Multiple Sclerosis in Iran Over the Past 30 Years, Multiple Sclerosis and Related Disorders (2022)
3. Comparison of Interferon Beta Products and Azathioprine in the Treatment of Relapsing-Remitting Multiple Sclerosis, Journal of Neurology (2007)
4. Rituximab and Glatiramer Acetate in Secondary Progressive Multiple Sclerosis: A Randomized Clinical Trial, Acta Neurologica Scandinavica (2021)
5. Neurological Efficacy and Safety of Mesenchymal Stem Cells (Mscs) Therapy in People With Multiple Sclerosis (Pwms): An Updated Systematic Review and Meta-Analysis, Multiple Sclerosis and Related Disorders (2024)
6. Predictors of Treatment Switching in the Big Multiple Sclerosis Data Network, Frontiers in Neurology (2023)
7. Confirmed Disability Progression As a Marker of Permanent Disability in Multiple Sclerosis, European Journal of Neurology (2022)
8. Disease Reactivation After Cessation of Disease-Modifying Therapy in Patients With Relapsing-Remitting Multiple Sclerosis, Neurology (2022)
Experts (# of related papers)
View all Related Experts
Vahid Shaygannejad (118)
Masoud Etemadifar (91)
Other Related Docs
9. Comparing the Efficacy of Monthly Cyclophosphamide As Monotherapy Versus Daily Fingolimod in Relapsing Remitting and Secondary Progressive Multiple Sclerosis, Journal of Isfahan Medical School (2017)
10. Safety and Efficacy of Cladribine in Multiple Sclerosis: A Systematic Review and Meta-Analysis, Neurological Sciences (2023)
11. Iranian Specialists’ Approach to Treatment Escalation in Multiple Sclerosis Patients With Cognitive Impairment, Current Journal of Neurology (2023)
12. Comparison of Betaferon, Avonex, and Rebif in Treatment of Relapsing-Remitting Multiple Sclerosis, Acta Neurologica Scandinavica (2006)
13. Towards Personalized Therapy for Multiple Sclerosis: Prediction of Individual Treatment Response, Brain (2017)
14. Efficacy and Safety of Peginterferon Beta-1A Compared to Interferon Beta-1A in Relapsing Remitting Multiple Sclerosis Patients: A Phase 3, Randomized, Non-Inferiority Clinical Trial (Pegintegrity), Multiple Sclerosis and Related Disorders (2024)
15. Mycophenolate Mofetil in Combination With Interferon Beta-1A in the Treatment of Relapsing-Remitting Multiple Sclerosis: A Preliminary Study, Journal of Research in Medical Sciences (2011)
16. Impact of Methodological Choices in Comparative Effectiveness Studies: Application in Natalizumab Versus Fingolimod Comparison Among Patients With Multiple Sclerosis, BMC Medical Research Methodology (2022)
17. Variability of the Response to Immunotherapy Among Subgroups of Patients With Multiple Sclerosis, European Journal of Neurology (2023)
18. Comparable Efficacy and Safety of Teriflunomide Versus Dimethyl Fumarate for the Treatment of Relapsing-Remitting Multiple Sclerosis, Neurology Research International (2021)
19. Comparison of Fingolimod, Dimethyl Fumarate and Teriflunomide for Multiple Sclerosis, Journal of Neurology, Neurosurgery and Psychiatry (2019)
20. External Validation of a Clinical Prediction Model in Multiple Sclerosis, Multiple Sclerosis Journal (2023)
21. Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Rapidly Evolving Severe Relapsing-Remitting Multiple Sclerosis in the United Kingdom, Journal of Medical Economics (2024)
22. First-Year Treatment Response Predicts the Following 5-Year Disease Course in Patients With Relapsing-Remitting Multiple Sclerosis, Neurotherapeutics (2025)
23. Comparative Effectiveness of Natalizumab, Fingolimod, and Injectable Therapies in Pediatric-Onset Multiple Sclerosis: A Registry-Based Study, Neurology (2024)
24. Time Interval Between the Onset of Symptoms and Diagnosis of Multiple Sclerosis and the Influential Factors: A National Registry-Based Study, Clinical Neurology and Neurosurgery (2024)
25. Neutralizing Antibodies in Multiple Sclerosis Patients on Weekly Intramuscular Avonex and Biosimilar Interferon Beta-1A (Cinnovex): Comparing Results of Measurements in Two Different Laboratories, Journal of Immunological Methods (2013)
26. Effectiveness of Multiple Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis: Causal Inference to Emulate a Multiarm Randomised Trial, Journal of Neurology, Neurosurgery and Psychiatry (2023)
27. Prevalence of Cognitive Impairment (Ci) in Patients With Multiple Sclerosis (Ms): A Systematic Review and Meta-Analysis, Caspian Journal of Internal Medicine (2024)
28. Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis, JAMA - Journal of the American Medical Association (2019)
29. The Effectiveness of Natalizumab Vs Fingolimod–A Comparison of International Registry Studies, Multiple Sclerosis and Related Disorders (2021)
30. Effect of Disease-Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years, Neurology (2021)
31. Mizaj Assessment in Multiple Sclerosis (Ms) Patients Based on Persian Medicine, Journal of Complementary and Integrative Medicine (2022)
32. Multiple Sclerosis: Pathogenesis, Symptoms, Diagnoses and Cell-Based Therapy, Cell Journal (2017)
33. Evaluating Efficacy and Safety of Ocrelizumab Biosimilar (Xacrel) Compared to the Originator (Ocrevus) in Relapsing Multiple Sclerosis: A Phase Iii, Randomized, Equivalency, Clinical Trial, Scientific Reports (2024)
34. Clinical Characteristics and Disability Progression of Early-And Late-Onset Multiple Sclerosis Compared to Adult-Onset Multiple Sclerosis, Journal of Clinical Medicine (2020)
35. Comparison Effect of Prescription Drugs on the Occurrence and the Number of Attacks in Patients With Multiple Sclerosis, Journal of Isfahan Medical School (2018)
36. Cyclophosphamide Versus Rituximab in Progressive Forms of Multiple Sclerosis, Acta Medica Iranica (2019)
37. Effects of Rivastigmine on Memory and Cognition in Multiple Sclerosis, Canadian Journal of Neurological Sciences (2008)
38. Multiple Sclerosis in Isfahan, Iran, International Review of Neurobiology (2007)
39. Risk and Severity of Sars-Cov-2 Reinfection Among Patients With Multiple Sclerosis Vs. the General Population: A Population-Based Study, BMC Neurology (2022)
40. Seasonal and Monthly Variation in Multiple Sclerosis Relapses: A Systematic Review and Meta-Analysis, Acta Neurologica Belgica (2022)
41. Efficacy and Safety of Rituximab in Multiple Sclerosis: A Systematic Review and Meta-Analysis, Acta Neurologica Belgica (2023)
42. Prevalence of Multiple Sclerosis in Isfahan, Iran, Neuroepidemiology (2006)
43. Comparing Side Effects of Cinnovex With Avonex in Relapsing Remitting Multiple Sclerosis Patients, Journal of Isfahan Medical School (2009)
44. Stress Differentially Predicts Multiple Sclerosis Relapses, Neurology Asia (2014)
45. Multiple Sclerosis Severity Score (Msss) Improves the Accuracy of Individualized Prediction in Ms, Multiple Sclerosis Journal (2022)
46. Interferon-Beta in Pediatric Multiple Sclerosis Patients: Safety in Short-Term Prescription, Acta Medica Iranica (2012)
47. The Effect of Ginger (Zingiber Officinale) Supplementation on Clinical, Biochemical, and Anthropometric Parameters in Patients With Multiple Sclerosis: A Double-Blind Randomized Controlled Trial, Food and Function (2023)
48. Late-Onset Multiple Sclerosis in Iran: A Report on Demographic and Disease Characteristics, Multiple Sclerosis and Related Disorders (2023)
49. Risk Factors of Severe Covid-19 in People With Multiple Sclerosis : A Systematic Review and Meta-Analysis, Revue Neurologique (2022)
50. Safety and Efficacy of Fingolimod in Iranian Patients With Relapsing-Remitting Multiple Sclerosis: An Open-Label Study, Caspian Journal of Internal Medicine (2021)